Delcath inks European licensing deal for Chemosat

Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe.

According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated to pay $6.8 million to Delcath in a combination of upfront and milestone payments.

Get the full story at our sister site, Drug Delivery Business News.

The post Delcath inks European licensing deal for Chemosat appeared first on MassDevice.

from MassDevice http://bit.ly/2QNMO4B